Special Drug Use Investigation of EYLEA for Quality of Life
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Bayer
- 02 Feb 2018 Status changed from active, no longer recruiting to completed.
- 17 Mar 2016 Planned End Date changed from 1 Sep 2020 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 17 Mar 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2016, as reported by ClinicalTrials.gov.